Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift®)

Publication date: Available online 13 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Sebastian Michels, Eugen Zizer, Thomas FE Barth, Anette Wassner, Tanja Fangerau, Daniela Taranu, Franziska Bachhuber, Hayrettin Tumani, Makbule SenelAbstractA 23-year old female was diagnosed with relapsing-remitting multiple sclerosis with two symptomatic attacks. Immunomodulatory treatment with Clift® (Glatiramer Acetate biosimilar) was initiated. Shortly after administration, an asymptomatic increase in liver enzymes was noticed, and therapy was paused. However, we observed an enormous increase in liver enzymes within a few days. Histological work up of a liver biopsy showed microfocal liver necrosis accompanied with increased numbers of CD38-positive lymphocytes as shown by immunohistology, indicating a drug-induced liver injury. Subsequently, under oral prednisolone treatment, liver enzymes normalized. This case highlights the importance of tight monitoring of liver function in the initial phase of a new immunotherapy to unravel asymptomatic hepatotoxicity in time and prevent further damage.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research